ATX-GD-59 Peptide Therapy - Breakthrough Graves’ Disease Treatment
ProcurenetShort description
Product Name: ATX-GD-59 Peptide Therapy, an advanced treatment targeted at the immunological root of Graves’ Disease. It’s marked by a catalog number GT-L002 with a molecular formula of C114H198N32O32 and molecular weight of 2529.26. It is seen as a white powdery substance with an HPLC purity greater than 98%. Available in package sizes including 10mg, 50mg, 100mg, 1g, 10g, and 50g, it’s advisable to store this product at -20°C, in a cool dry place, away from light without exposure to drastic temperature changes. Unfortunately, a CAS number is not provided.
$0
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
ATX-GD-59 Peptide Therapy: Advanced Treatment for Graves' Disease
Introducing ATX-GD-59, catalog No. GT-L002, an innovative peptide-based therapy developed expressly for the treatment of Graves' disease. Engineered with a molecular weight of 2529.26 and a molecular formula of C114H198N32O32, ATX-GD-59 adheres to the most rigorous research-grade standards, indicating our commitment to quality and innovation.
ATX-GD-59 revolutionizes the medical landscape with its novel mechanism of action, designed to mimic epitopes, effectively immobilizing the leukocytes responsible for attacking the thyroid, and obstructing the creation of anti-thyroid stimulating hormone receptor (TSHR) stimulatory antibodies. This advanced approach transcends traditional therapeutics, directing the focus towards the immunological cornerstone of Graves' disease. Essentially, ATX-GD-59 is setting a new path in disease treatment.
Our product has undergone stringent clinical trials to establish its safety and high level of tolerability. It boasts an impressive specification of purity (HPLC) over 98.0%, single impurity less than 1.5%, peptide content above 70.0%, and all this while maintaining accurate amino acid composition within +- 10%.
Delivered in the form of white powder and sealed in an aluminium foil or transparent bag, ATX-GD-59 offers flexibility with packaging options ranging from 10mg to 50g to cater to varying scales of research requirements. Furthermore, maintaining optimal storage in a cool, dry environment, away from direct light and ideally at -20°C, ensures the product's longevity and efficacy.
Please be informed that ATX-GD-59 is intended exclusively for research purposes and is not recommended for human consumption.
Key Features of ATX-GD-59:
- Innovative peptide-based therapy targeted for Graves' disease
- Immunological approach inhibits leukocyte activity
- Stops the creation of anti-TSHR stimulatory antibodies.
- Purity assurance of over 98.0% (HPLC)
- Proven safety and high tolerability from rigorous clinical trials
- Flexible packaging options suiting diverse research needs
- Recommended storage for maximum product efficacy
